진매트릭스
Financials
Valuation Metrics
진매트릭스's Market Cap is ₩325B. At end of 2025 it was ₩501B. Ranked #2034 of 2,421 in KR market (top 84%), #1293 of 1,640 on KOSDAQ (top 79%), #213 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 92%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 32.47B KRW | KR#2,034/2,421 Sec#213/231 |
| Revenue | 10.88B KRW | KR#2,278/2,421 Sec#173/231 |
| Net Income | -189.9M KRW | KR—/2,421 Sec—/231 |
| Total Assets | 27.59B KRW | KR#2,351/2,421 Sec#223/231 |
| Net Assets | 17.94B KRW | KR#2,314/2,421 Sec#217/231 |
| Employees | 67 | KR#1,914/2,421 Sec#167/231 |
| Value | ||
| P/B | 1.81x | KR#1,877/2,421 Sec#137/231 |
| P/S | 2.98x | KR#1,981/2,421 Sec#124/231 |
| FCF Yield | 3.78% | KR#936/2,421 Sec#55/231 |
| Profitability | ||
| ROE | -1.06% | KR#1,625/2,421 Sec#111/231 |
| ROA | -0.69% | KR#1,636/2,421 Sec#111/231 |
| Op. Margin | -2.15% | KR#1,749/2,421 Sec#118/231 |
| Revenue Growth | 4.17% | KR#1,251/2,421 Sec#126/231 |
| Financial Health | ||
| Debt Ratio | 53.83% | KR#1,015/2,421 Sec#118/231 |
| Total Debt | 3.60B KRW | KR#1,842/2,421 Sec#178/231 |
| FCF | 1.23B KRW | KR#1,135/2,421 Sec#82/231 |
| Cash | 5.66B KRW | KR#1,966/2,421 Sec#179/231 |
| Current Ratio | 4.77x | KR#307/2,421 Sec#52/231 |
| Performance | ||
| 1Y Return | -49.14% | KR#2,040/2,421 Sec#183/231 |
| 1M Return | 11.56% | KR#431/2,421 Sec#29/231 |
| From 52W High | -58.49% | KR#1,798/2,421 Sec#135/231 |
| 1Y MDD | -59.51% | KR#1,453/2,421 Sec#115/231 |
| Trading | ||
| Volume | 18,327 shares | KR#1,630/2,421 Sec#159/231 |
| Trading Value | 29.1M KRW | KR#2,042/2,421 Sec#206/231 |
| Foreign Own. | 1.57% | KR#1,808/2,421 Sec#177/231 |
| Per Share | ||
| EPS | -9 KRW | KR—/2,421 Sec—/231 |
| BPS | 880 KRW | KR#2,328/2,421 Sec#215/231 |
Company Info
Genematrix, established in 2000 and headquartered in Seongnam-si, Gyeonggi-do, was founded to develop pharmaceuticals and diagnostics using biotechnology, listing on KOSDAQ in 2009. The company develops and sells medical diagnostic reagents, including molecular diagnostics and biochemical reagents, leveraging its proprietary technologies. It is also developing vaccines and immuno-oncology therapeutics for disease prevention and treatment. Genematrix possesses multiplex testing technology through key products for diagnosing sexually transmitted infections, tuberculosis, and human papillomavirus, facilitating its expansion into global markets.